ProKidney Names Farah Ali Chief Medical Officer
The cell therapy company elevated its clinical leader to the top medical role as it advances its kidney disease program.
Updated on Nov. 18, 2026 in People

ProKidney Corp. promoted Farah Ali, M.D., M.S., to Chief Medical Officer, a role in which she will lead the company's clinical program and team. The announcement was made from Winston-Salem, N.C.
Why it matters
The promotion places a senior clinical development leader in charge of the medical strategy for a late clinical-stage chronic kidney disease company. The move comes as ProKidney prepares for anticipated clinical milestones and regulatory filings for its lead candidate.
ProKidney was founded in 2015 and expects its current cash, cash equivalents and marketable securities to support operating plans into mid-2027. Ali brings more than a decade of clinical development and medical affairs experience to the role.
The players
ProKidney Corp.
A late clinical-stage cell therapy company founded in 2015 that is developing treatments for chronic kidney disease, with rilparencel (also known as REACT) as its lead product candidate.
Farah Ali, M.D., M.S.
A board-certified pediatric nephrologist and clinical development executive who previously held senior roles at Immunovant, Amgen and Horizon Therapeutics.
The details
Ali previously served as Senior Vice President, Clinical Development at Immunovant, Vice President, Clinical Development for Rare Disease at Amgen, and Vice President, Clinical Development at Horizon Therapeutics. She is board certified in pediatric nephrology and began her career on the faculty at Northwestern University Feinberg School of Medicine.
Timeline
2015: ProKidney Corp. is founded.
November 18, 2026: ProKidney announces Farah Ali's promotion to Chief Medical Officer.
Mid-2027: Current cash is expected to support ProKidney's operating plans.
Season Trajectory
The appointment places a clinical development executive in charge of ProKidney's Phase 3 PROACT 1 study of rilparencel, the program on which the company's near-term regulatory path depends. It signals that the company is focusing its medical leadership on the milestones needed to move the therapy toward potential commercialization.
For North Carolina readers, the appointment has no direct effect on patients or prices today. Its practical significance lies in whether the clinical program under Ali's leadership reaches the regulatory filings and milestones the company has said it is preparing for.
The takeaway
Leadership changes in clinical-stage biotechnology often signal which milestones a company is prioritizing next. Readers following the company should watch for updates on its regulatory filings and the rilparencel development program.
Further reading
Explore more business people appointments coverage from across North Carolina.
More information
Learn more about the company on its ProKidney Corp. company information page.
Source note: This article includes information reported by The Manila times.






